Format

Send to

Choose Destination
Br J Cancer. 2018 May;118(11):1485-1491. doi: 10.1038/s41416-018-0093-y. Epub 2018 May 14.

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.

Author information

1
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, Berlin, 10117, Germany. philipp.lohneis@uk-koeln.de.
2
University Hospital Cologne, Institute of Pathology, Kerpener Strasse 62, Köln, 50924, Germany. philipp.lohneis@uk-koeln.de.
3
Department of Medical Oncology, CONKO study group, Haematology and Tumorimmunology, Augustenburger Platz 1, Berlin, 13353, Germany.
4
Department of Surgery Campus Charité Mitte/ Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, 13353, Germany.
5
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, Berlin, 10117, Germany.
6
Outpatient Department Hematology/Oncology, Friedrichstrasse 53, Friedrichshafen, 88045, Germany.

Abstract

BACKGROUND:

The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial.

METHODS:

Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0.238 mm2).

RESULTS:

Tumour budding was significantly associated with a higher tumour grade (p < 0.001) but not with distant or lymph node metastasis. Regardless of the quantification approach, an increased number of tumour buds was significantly associated with reduced disease-free survival (DFS) and overall survival (OS) (10 HPF approach DFS: HR = 1.056 (95% CI 1.022-1.092), p = 0.001; OS: HR = 1.052 (95% CI 1.018-1.087), p = 0.002; consensus method DFS: HR = 1.037 (95% CI 1.017-1.058), p < 0.001; OS: HR = 1.040 (95% CI 1.019-1.061), p < 0.001). Recently published cut-offs for tumour budding in colorectal cancer were prognostic in PDAC as well.

CONCLUSIONS:

Tumour budding is prognostic in the CONKO-001 clinical cohort of patients. Further standardisation and validation in additional clinical cohorts are necessary.

PMID:
29755112
PMCID:
PMC5988658
DOI:
10.1038/s41416-018-0093-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center